Mutational Testing

Home/Mutational Testing

Collaborative Effort Produces Position Paper on Need for Advanced Biomarker Testing

The Life Raft Group was recently part of team of authors on a collaborative position paper entitled 'Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type published' in Pathology: The Journal of the Royal College of Pathologists of Australia.

By |2022-08-15T16:05:39-04:00August 15th, 2022|Mutational Testing, News, Research|

The Value of Biomarker Testing: Case Studies Across Multiple Institutions

In this webinar, there were case study presentations from three top sarcoma institutions that demonstrate the value of biomarker testing. A Question & Answer session followed the presentations.

By |2022-02-08T12:01:53-05:00January 12th, 2022|Mutational Testing, Webcast|

Tissue Testing Project

The Life Raft Group (LRG) is providing you with this information to let you know that comprehensive genomic profiling, also known as biomarker testing or molecular testing, is a crucial step in understanding the genomic factors that play a role in a GIST diagnosis. Bayer Pharmaceuticals, in partnership with The Life Raft Group (LRG), has extended a research collaboration to broaden access to comprehensive genomic testing (CGT) for Gastrointestinal Stromal Tumor (GIST) patients.

By |2021-11-04T10:18:38-04:00October 27th, 2021|Mutational Testing, News|

The Importance of Biomarker Testing for the Effective Treatment of GIST Patients – LRG Science

This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient's journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.

By |2021-09-27T07:30:29-04:00August 30th, 2021|LRG Science, Mutational Testing, News|

‘It’s Time’ to Continue Our Message About Biomarker Testing!

So far in 2021, our 'It's Time' campaign has emphasized twelve important points concerning biomarker testing and the important role it plays in a GIST patient's journey. We will keep the momentum going with patient stories, webinars, and resource materials.

By |2021-09-27T14:30:56-04:00July 22nd, 2021|Mutational Testing, News|

It’s Time: The Life Raft Group Biomarker Testing Campaign – It’s Time to Save Lives!

Biomarker testing is an opportunity to improve and optimize treatment. In this post, GISTer Bill Borwegen shares his story and we share how you can help save lives.

By |2021-09-27T14:32:40-04:00July 1st, 2021|Mutational Testing, News|
Go to Top